Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 25:5:Doc04.
doi: 10.3205/id000030. eCollection 2017.

Influenza viruses - antiviral therapy and resistance

Susanne Duwe  1
Affiliations
Review

Influenza viruses - antiviral therapy and resistance

Susanne Duwe. GMS Infect Dis. .

Abstract

Influenza is a serious and frequently underestimated, but vaccine preventable disease. The adamantane derivates rimantadine and amantadine and the neuraminidase inhibitors zanamivir and oseltamivir are the only antiviral drugs currently approved in Europe for therapy and prophylaxis of influenza infections. Resistance to these drugs occurs due to mutations within the therapeutic target proteins M2 ion channel protein and viral neuraminidase. An unexpected occurrence of oseltamivir-resistant seasonal A(H1N1) viruses was detected in winter 2007/2008. The prevalence of these viruses increased rapidly and nearby all viruses circulating during the following seasons were resistant to oseltamivir. The A(H1N1)pdm09 viruses replaced the former seasonal A(H1N1) subtype during the 2009-2010 influenza season. Fortunately, resistance to neuraminidase inhibitors was detected in A(H1N1)pdm09, A(H3N2) and influenza B viruses only sporadically and was treatment related mostly. Comprehensive analyses of circulating viruses showed a high prevalence of A(H3N2) influenza viruses that are resistant to adamantane derivates since 2004/2005 and a progressive trend in the prevalence of resistant viruses up to 100% in following seasons. The M2 ion channel protein of A(H1N1)pdm09 viruses is associated with the Eurasian avian-like swine lineage and thus show "natural" resistance to adamantane derivates. Therefore, only neuraminidase inhibitors are recommended for influenza treatment today. This manuscript summarizes the occurrence and spread of antiviral resistant influenza viruses and highlights the importance for developing and/or approving new antiviral compounds.

Keywords: antiviral resistance; infection; monitoring; neuraminidase; surveillance.

PubMed Disclaimer

Conflict of interest statement

The author declares that she has no competing interests.

Figures

Table 1
Table 1. List of anti-influenza drugs recently approved or under clinical trials
Table 2
Table 2. Influenza antiviral resistance testing
See this image and copyright information in PMC

References

    1. Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, editors. Virus taxonomy. Classification and nomenclature of viruses. Eighth report of the International Committee on Taxonomy of Viruses. Amsterdam, Boston: Elsevier Academic Press; 2005.
    1. Kawaoka Y, Neumann G. Influenza Viruses: An Introduction. In: Kawaoka Y, Neumann G, editors. Influenza Virus: Methods and Protocols. New York et al.: Humana, Springer; 2012. pp. 1–9. - DOI
    1. Shi Y, Wu Y, Zhang W, Qi J, Gao GF. Enabling the 'host jump': structural determinants of receptor-binding specificity in influenza A viruses. Nat Rev Microbiol. 2014 Dec;12(12):822–831. doi: 10.1038/nrmicro3362. - DOI - PubMed
    1. Arvia R, Corcioli F, Pierucci F, Azzi A. Molecular markers of influenza B lineages and clades. Viruses. 2014 Nov;6(11):4437–4446. doi: 10.3390/v6114437. - DOI - PMC - PubMed
    1. Earn DJD, Dushoff J, Levin SA. Ecology and evolution of the flu. Trends Ecol Evol. 2002 Jul;17(7):334–340. doi: 10.1016/S0169-5347(02)02502-8. - DOI